You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Details for New Drug Application (NDA): 017813


✉ Email this page to a colleague

« Back to Dashboard


NDA 017813 describes LIBRELEASE, which is a drug marketed by Valeant Pharm Intl and is included in one NDA. Additional details are available on the LIBRELEASE profile page.

The generic ingredient in LIBRELEASE is chlordiazepoxide. There are nine drug master file entries for this compound. Additional details are available on the chlordiazepoxide profile page.
Summary for 017813
Tradename:LIBRELEASE
Applicant:Valeant Pharm Intl
Ingredient:chlordiazepoxide
Patents:0
Medical Subject Heading (MeSH) Categories for 017813

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:CAPSULE, EXTENDED RELEASE;ORALStrength30MG
Approval Date:Sep 12, 1983TE:RLD:No

Expired US Patents for NDA 017813

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Pharm Intl LIBRELEASE chlordiazepoxide CAPSULE, EXTENDED RELEASE;ORAL 017813-001 Sep 12, 1983 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.